What's new? Log in Free sign up

Home
Sectors & IndustriesSectors
Earnings
IPOs
Transcripts
Insider
Institutional
Splits

ARGX Dashboard
Financials
Filings
Holdings
Transcripts
ETFs
Insider
Institutional
Shorts
6-K Filing

argenx SE (ARGX) 6-KCIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada

Filed: 31 Oct 24, 8:15am

Free signup for more

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news and more
Access all data and search results

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of contents

Filing tables

Export all tables to Excel

Filing exhibits

6-K Current report (foreign)
99.1 EX-99.1
99.2 EX-99.2

ARGX similar filings

20 Nov 24 Current report (foreign)
12 Nov 24 First and only NMPA-approved treatment for patients with CIDP in China
31 Oct 24 CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada
15 Oct 24 Current report (foreign)
19 Sep 24 Current report (foreign)
25 Jul 24 Current report (foreign)

Filing view

Default size S M L
Default font Times Arial

External links

View on EDGAR (sec.gov)

Share this filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2024

Commission File Number: 001-38097

ARGENX SE

(Translation of registrant’s name into English)

Laarderhoogteweg 25
1101 EB Amsterdam, the Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

On October 31, 2024, argenx SE (the “Company’’) issued a press release and investor presentation, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

The information contained in this Current Report on Form 6-K, including Exhibit 99.1 and Exhibit 99.2, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Forms F-3 (File No. 333-258251) and S-8 (File Nos. 333-225375, 333-258253, and 333-274721), and to be part thereof from the date on which this Current Report on Form 6-K is

filed, to the extent not superseded by documents or reports subsequently filed or furnished.


EXHIBITS
Exhibit						Description
99.1						Press Release dated October 31, 2024
99.2						Investor Presentation dated October 31, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		ARGENX SE
Date: October 31, 2024	By:	/s/ Hemamalini (Malini) Moorthy
		Hemamalini (Malini) Moorthy
		General Counsel

Resources

Knowledgebase
Log In
Register

Company

About
Contact
Solutions

Products

Deal Roadshow
DealVDR
Evercall
Finsight.com

CapEdge

Earnings Calendar
Earnings Transcripts
EDGAR Filing Screener
IPO Calendar

Compliance
Privacy
Security
Terms

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.